SCHEMBL3380746

SCHEMBL3380746

Oc1nccc2ccc(Cl)nc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.33
MMP2 P08253 2/20 0.33
TSHR P16473 2/20 0.33
KDM4E B2RXH2 2/20 0.33
LMNA P02545 2/20 0.33
TP53 P04637 2/20 0.33
HSP90AA1 P07900 2/20 0.33
CYP3A4 P08684 2/20 0.33
MMP9 P14780 2/20 0.33
ALOX15 P16050 2/20 0.33
HTT P42858 2/20 0.33
MMP13 P45452 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
TDP1 Q9NUW8 2/20 0.33
GMNN O75496 1/20 0.33
CYP2D6 P10635 1/20 0.33
NFKB1 P19838 1/20 0.33
MMP8 P22894 1/20 0.33
CCR1 P32246 1/20 0.33
THPO P40225 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30670499 0.78 LMNA (0.38) MAPTMMP2TSHRKDM4ELMNA
SCHEMBL24716239 0.78 LMNA (0.38) MAPTMMP2TSHRKDM4ELMNA
SCHEMBL30564984 0.75 CCR1 (0.56) MAPTKDM4ELMNATP53HTT
SCHEMBL6221465 0.75 KDM4E (0.35) MAPTMMP2TSHRKDM4ELMNA
SCHEMBL16463280 0.75 NOS3 (0.41) MAPTMMP2TSHRKDM4ELMNA
SCHEMBL13313410 0.75 CCR1 (0.56) MAPTKDM4ELMNATP53HTT
SCHEMBL29533844 0.74 CCR1 (0.43) MAPTMMP2TSHRKDM4ELMNA
SCHEMBL557084 0.74 CCR1 (0.43) MAPTMMP2TSHRKDM4ELMNA
SCHEMBL29772312 0.71 MCHR1 (0.36) MAPTKDM4ECYP3A4SMN1; SMN2CYP2D6
SCHEMBL23169319 0.71 MCHR1 (0.36) MAPTKDM4ECYP3A4SMN1; SMN2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1934216-B1 NAPHTHYRIDIN DERIVATIVES HOFFMANN LA ROCHE (CH) 2010-11-24 EP disclosed
EP-1934216-B1 NAPHTHYRIDIN DERIVATIVES HOFFMANN LA ROCHE (CH) 2010-11-24 EP disclosed
US-7511055-B2 Naphthyridin derivatives HOFFMANN-LA ROCHE INC. (US) 2009-03-31 US disclosed
US-7511055-B2 Naphthyridin derivatives HOFFMANN-LA ROCHE INC. (US) 2009-03-31 US disclosed
US-7511055-B2 Naphthyridin derivatives HOFFMANN-LA ROCHE INC. (US) 2009-03-31 US disclosed
EP-1934216-A1 NAPHTHYRIDIN DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-06-25 EP disclosed
WO-2007039512-A1 NAPHTHYRIDIN DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-04-12 WO disclosed
WO-2007039512-A1 NAPHTHYRIDIN DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-04-12 WO disclosed
US-20070078155-A1 Naphthyridin derivatives F. HOFFMANN-LA ROCHE AG (CH) 2007-04-05 US disclosed
US-20070078155-A1 Naphthyridin derivatives F. HOFFMANN-LA ROCHE AG (CH) 2007-04-05 US disclosed
US-20070078155-A1 Naphthyridin derivatives F. HOFFMANN-LA ROCHE AG (CH) 2007-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078155-A1 Naphthyridin derivatives GRM5, GRM3, GRM1 MAPT 2060/4885MMP2 4627/4885TSHR 305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.